Avanos Medical, Inc. (AVNS)
NYSE: AVNS · IEX Real-Time Price · USD
18.71
-0.05 (-0.27%)
Apr 24, 2024, 4:00 PM EDT - Market closed
Avanos Medical Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Avanos Medical stock have an average target of 27.33, with a low estimate of 25 and a high estimate of 31. The average target predicts an increase of 46.07% from the current stock price of 18.71.
Analyst Consensus: Hold
* Price targets were last updated on Jun 21, 2023.
Analyst Ratings
The average analyst rating for Avanos Medical stock from 4 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Keybanc | Keybanc | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Jul 25, 2023 |
| Stifel | Stifel | Hold Reiterates $25 | Hold | Reiterates | $25 | +33.62% | Jun 21, 2023 |
| CL King | CL King | Strong Buy Initiates $31 | Strong Buy | Initiates | $31 | +65.69% | May 22, 2023 |
| Morgan Stanley | Morgan Stanley | Sell Maintains $28 → $26 | Sell | Maintains | $28 → $26 | +38.96% | May 4, 2023 |
| Morgan Stanley | Morgan Stanley | Sell Maintains $26 → $28 | Sell | Maintains | $26 → $28 | +49.65% | Feb 22, 2023 |
Financial Forecast
Revenue This Year
704.82M
from 673.30M
Increased by 4.68%
Revenue Next Year
743.21M
from 704.82M
Increased by 5.45%
EPS This Year
1.40
from -1.32
EPS Next Year
1.89
from 1.40
Increased by 34.40%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 727.7M | 766.5M | 807.4M | 871.1M |
| Avg | 704.8M | 743.2M | 784.3M | 846.2M |
| Low | 676.2M | 711.5M | 753.5M | 813.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 8.1% | 8.8% | 8.6% | 11.1% |
| Avg | 4.7% | 5.4% | 5.5% | 7.9% |
| Low | 0.4% | 0.9% | 1.4% | 3.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 1.45 | 1.98 | 2.13 | 2.60 |
| Avg | 1.40 | 1.89 | 2.07 | 2.53 |
| Low | 1.34 | 1.77 | 1.99 | 2.43 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | 41.3% | 12.9% | 25.8% |
| Avg | - | 34.4% | 9.7% | 22.2% |
| Low | - | 26.3% | 5.4% | 17.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.